Sentence examples for mutation for resistance from inspiring English sources

No major mutation for resistance to non-NRTIs was found.

Etravirine is a diarylpyrimidine compound that was specifically designed to bind to HIV-1 reverse trancriptase in a more flexible manner than efavirenz and nevirapine and to require more than one key NNRTI resistance mutation for resistance development 37– 39(ie, to possess a higher genetic hurdle to resistance).

These assayed lysates should be easily large enough to harbor rare spontaneous mutants; although the mutation rate and mutation spectrum for 45°C heat-shock resistance are unknown in φ6, we can expect between 10-4 and 10-6 particleshouldld contain a point mutation for resistance to a selective challenge such as growth on a novel host [ 21, 35].

Six of the 44 (13.6%) HIV-1 strains had mutations for resistance to PIs and non-NRTIs, and one (2.3%) was resistant to both NRTIs and non-NRTIs.

A complete analysis of G glycoprotein sequences from GenBank demonstrated that no identified rabies isolates contain the necessary combination of G glycoprotein mutations for resistance to RAB1 neutralization, consistent with the broad neutralization of RAB1 observed in direct viral neutralization experiments with street isolates.

New drugs targeting HIV replication by blocking ERK1/2 phosphorylation of MA and Vif could in theory be incorporated into existing therapy regimens, making it more difficult for an HIV strain to acquire the mutations for resistance to all drugs [26].

We found that 2.8% were major mutations for resistance to PIs (1.9%) and NRTIs (0.9%), providing little evidence for transmitted resistance to ARVs among untreated pregnant women in central Africa.

This is only to be expected given enough time for selection to act as long as a less costly mutation (or a combination of mutations) for resistance is available to the bacterium.

In all, 44/107 (41.1%) HIV-1 strains presented minor or major genotypic resistance to ARVs, of which 3/107 (2.8%) were major mutations for resistance to PIs (n = 2/107, 1.9%) and NRTIs (n = 1/107, 0.9%).

Indeed, clinical data confirmed the predictive value of KRAS exon 2 mutations for resistance to cetuximab and panitumumab, leading to the license of these moAbs exclusively for the management of patients with KRAS-wild type colorectal cancers [ 5- 7].

Prior to the study, only 8 percent of A. gambiae mosquitoes carried the genetic mutation responsible for resistance.